Results 11 to 20 of about 29,283 (148)

The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population [PDF]

Clinical and Experimental Hypertension, 2017
Numerous studies demonstrated an importance of cytochrome P-450 epoxygenase pathway of arachidonic acids metabolism for the pathogenesis of essential hypertension (EH).
Alexey Polonikov, Marina Bykanova, Irina Ponomarenko, Svetlana Sirotina, Anna Bocharova, Kseniya Vagaytseva, Vadim Stepanov, Mikhail Churnosov, Olga Bushueva, Maria Solodilova, Yaroslav Shvetsov, Vladimir Ivanov   +11 more
doaj   +2 more sources

Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects [PDF]

Neuropsychiatric Disease and Treatment, 2020
Alessandra Morano,1 Martina Fanella,1 Mariarita Albini,1 Pierangelo Cifelli,2,3 Eleonora Palma,2 Anna Teresa Giallonardo,1 Carlo Di Bonaventura1 1Epilepsy Unit, Department of Human Neurosciences, “Sapienza” University of Rome, Rome, Italy ...
Morano A, Fanella M, Albini M, Cifelli P, Palma E, Giallonardo AT, Di Bonaventura C   +6 more
doaj   +3 more sources

Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency [PDF]

, 2010
Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency(ORD) present with disordered sex development and glucocorticoid deficiency.
Arlt, Bebia, Chang, de Morais, Dominique Maiter, Dorota Tomalik-Scharte, Fl  ck, Fuhr, Gomes, Hannah E Ivison, Henderson, Jetter, Julia Kirchheiner, Kelley, Kirchheiner, Kranendonk, Nebert, Nicolo, Parkinson, Porter, Ribes, Sachse, Tantcheva-Po  r, Tomalik-Scharte, Uwe Fuhr, Wiebke Arlt   +25 more
core   +2 more sources

Genetic polymorphism of cytochrome p450 (2C19) enzyme in Iranian Turkman ethnic group [PDF]

, 2013
Objective: Different findings indicate that CYP2C plays a clinical role in determining interindividual and interethnic differences in drug effectiveness. The ethnic differences in the frequency of CYP2C19 mutant alleles continue to be a significant study
Ataby, O.A., Mansourian, A.R., Marjani, A., Samai, N.M., Tabari, R.G.   +4 more
core   +2 more sources

Towards the clinical implementation of pharmacogenetics in bipolar disorder. [PDF]

, 2014
BackgroundBipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide.
A Berghofer, A Heils, A Koski, A Serretti, A Serretti, A Serretti, A Szczepankiewicz, A Yu, AA Nierenberg, AK Malhotra, AL Zackrisson, B Alsina, B Kremeyer, C Cordon-Cardo, C Kawanishi, C O’Dushlaine, C Sears, CA Grimes, CC Zai, CE Begley, CH Chen, DA Mrazek, DE Adkins, DJ Smith, DK Hall-Flavin, DK Hall-Flavin, DL Braff, E Lessard, E Schaeffeler, EB Binder, EB Brown, EG Jonsson, EJ Peters, EK Green, EM Penas-Lledo, EM Penas-Lledo, EN Smith, ER Mardis, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, F Asztely, F Benedetti, F Czerwensky, F Holsboer, F Mamdani, FJ Gonzalez, FJ McMahon, FM Daray, FP Bymaster, FP Guengerich, FR Sallee, G Shaltiel, G Turecki, GE Simon, GENDEP Investigators, MARS Investigators, STAR*D Investigators, GR Lewin, GS Malhi, GS Sachs, H Pei, HA Garriock, HK Kroemer, I Johansson, IC Gray, J Brockmoller, J de Leon, J de Leon, J de Leon, J de Leon, J Kirchheiner, J Kirchheiner, J Thome, J Winner, JA Engelman, JA Johnson, JA Lieberman, JC Ballenger, JC Chambers, JC Stingl, JE Kootstra-Ros, JE Sarginson, JK Rybakowski, JK Rybakowski, JM Beaulieu, John R Kelsoe, JP Zhang, JP Zhang, JR Kelsoe, JS Leeder, JT Groves, K Herrlin, K Hodgson, K Yoshii, KG Mountjoy, KL Kopnisky, KR Crews, KW Lobello, L Bertilsson, L Michelon, L Tondo, LA Smith, LN Yatham, LV Kessing, M Adli, M Dmitrzak-Weglarz, M Gex-Fabry, M Ingelman-Sundberg, M Man, M Ramsjo, M Sanford, M Tseng, M Uhr, MA Kohli, MA Martin, MD Ritchie, ME van den Akker-van Marle, MH Tsai, Michael J McCarthy, MJ Arranz, MJ McCarthy, MJ Neville, ML Dahl, Naji C Salloum, OL de Klerk, OV Olesen, P Grof, P Huezo-Diaz, P Sklar, PS Klein, Psychiatric GWAS Consortium Bipolar Disorder Working Group, R Calati, R Hashimoto, RA Philibert, RC Kessler, RH Perlis, RH Perlis, RH Perlis, RH Perlis, RH Weisler, RJ Loos, RM Hirschfeld, RM Post, RS Seelan, S Horstmann, S Kapur, S Kapur, S Mallal, S Paddock, S Steinberg, S Ulrich, SC Sim, SG Leckband, SH Sindrup, SI Hung, SJ Gardiner, SL McElroy, Susan G Leckband, SV Ambudkar, T Bremer, T Masui, T Rau, T Ritchie, T Suppes, TD Gould, TE Klein, TL Horvath, V De Luca, VL Ellingrod, W Steimer, WB Denny, WH Chung, YF Lin, YF Zou, Z Wang, Z Wang   +172 more
core   +3 more sources

Genetic risk factors of cytolysis syndrome in the treatment of recrudescence of chronic cardiovascular diseases

Российский кардиологический журнал, 2018
Aim. To assess the clinical, biochemical, and genetic risk factors for the development of hepatocyte cytolysis syndrome in patients with a combination of fatty liver disease and recrudescence of chronic cardiovascular pathology.Material and methods.
N. V. Kokh, E. N. Voronina, T. V. Efremova, G. S. Soldatova, G. I. Lifshits   +4 more
doaj   +1 more source

Economic evaluations of pharmacogenetic and pharmacogenomic screening tests : a systematic review : second update of the literature [PDF]

, 2016
Objective : Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature. Methods : A literature search was
Annemans, Lieven, Berm, Elizabeth JJ, Boersma, Cornelis, de Looff, Margot, Postma, Maarten J, van Boven, Job FM, Vegter, Stefan, Wilffert, Bob   +7 more
core   +6 more sources

The Pharmacogenetics of Cytochrome P450 2C19 Enzymes - Effects on Clopidogrel and Proton Pump Inhibitors [PDF]

, 2014
BACKGROUND: Cytochrome P450 (CYP) enzymes play important roles in human, including drug metabolism. CYP2 is the largest family of human CYP, with its sequence comprising almost one third of all CYP sequences, and responsible for the metabolism of ...
Muliaty, D. (Dewi), Yusmiati, Y. (Yusmiati)   +1 more
core   +4 more sources

Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.

Acta Pharmacologica et Toxicologica, 2000
Silibinin, the main constituent of silymarin, a flavonoid drug from silybum marianum used in liver disease, was tested for inhibition of human cytochrome P-450 enzymes.
S. Beckmann-Knopp, S. Rietbrock, R. Weyhenmeyer, Ronald H. Bocker, K. Beckurts, W. Lang, Miriam Hunz, U. Fuhr   +7 more
semanticscholar   +1 more source

Metabolism of six CYP probe substrates in fetal hepatocytes

ADMET and DMPK, 2016
Cytochrome P-450 (CYP) are the most common drug metabolizing enzymes and are abundantly expressed in liver apart from kidney, lungs, intestine, brain etc. Their expression levels change with physiological conditions and disease states.
Abdul Naveed Shaik, Sandeep Kumar Vishwakarma, Aleem A Khan   +2 more
doaj   +1 more source